|
|
|
|
CampathSan Antonio Business Journal, ILEX developed Campath, the only monoclonal antibody approved by the Food and Drug Administration for the treatment of patients with B-cell chronic lymphocytic ... Genzyme Names New Head of Product Development for Campath and ... Jan 13, 2006 Financial News USA (press release), FNWU) Genzyme Corp. (Nasdaq:GENZ) promoted Terry Murdock to lead product development of the oncology drug Campath. Murdock is the ... Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue Jan 9, 2006 MSN Money Oncology revenue includes profits and royalties from Campath(R) (alemtuzumab for injection), which is marketed by Schering AG and its US affiliate Berlex ... GENZYME: Pipeline Highlights Jan 12, 2006 Webbolt Business News (subscription), Genzyme and Schering AG Germany plan to initiate a Phase 3 clinical trial in the first half of this year evaluating Campath for the treatment of multiple ... GX15-070 Active in Refractory CLL Jan 10, 2006 Cancer Consultants (press release), ...activity in patients with chronic lymphocytic leukemia (CLL) who have stopped responding to standard therapies including chemotherapy, Rituxan®, and Campath ... Small Molecule Bcl-2 Protein Inhibitor, GX15-070, Active for ... Jan 12, 2006 Cancer Consultants (press release), The current study enrolled 25 patients with CLL refractory to fludarabine, alkylators and to Rituxan® and 40% had received a Campath® (lemtuzumab). ... Early numbers from Genzyme show 24% revenue rise Jan 9, 2006 Boston Business Journal, ...its $1 billion purchase of Ilex Oncology Inc., pursued in large part to tap into that company's cancer drugs now under development or like Campath, for sale. ... New Study Reinforces Increased Life Expectancy with MabCampath(R) ... Dec 13, 2005 PR Newswire UK (press release), MabCampath, also marketed as Campath(R) in the United States, is the first and only humanized monoclonal antibody approved for CLL and the first drug with ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |